

# Rupert Sandbrink

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10454730/publications.pdf>

Version: 2024-02-01

39  
papers

5,252  
citations

186209

28  
h-index

315616

38  
g-index

40  
all docs

40  
docs citations

40  
times ranked

6450  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 193-201.	2.5	693
2	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. <i>Lancet</i> , The, 2007, 370, 389-397.	6.3	468
3	Analysis of Heterogeneous $\beta$ A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay. <i>Journal of Biological Chemistry</i> , 1996, 271, 22908-22914.	1.6	461
4	Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. <i>JAMA Neurology</i> , 2014, 71, 306.	4.5	402
5	250 $\mu$ g or 500 $\mu$ g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. <i>Lancet Neurology</i> , The, 2009, 8, 889-897.	4.9	377
6	One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema. <i>Ophthalmology</i> , 2012, 119, 1658-1665.	2.5	340
7	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. <i>Lancet Neurology</i> , The, 2009, 8, 987-997.	4.9	322
8	Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. <i>Annals of Neurology</i> , 2011, 70, 897-912.	2.8	314
9	Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion. <i>Ophthalmology</i> , 2014, 121, 202-208.	2.5	243
10	Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. <i>Lancet Neurology</i> , The, 2009, 8, 1111-1119.	4.9	233
11	The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema. <i>Ophthalmology</i> , 2011, 118, 1819-1826.	2.5	233
12	Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study. <i>American Journal of Ophthalmology</i> , 2014, 158, 1032-1038.e2.	1.7	142
13	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. <i>JAMA Neurology</i> , 2015, 72, 1458.	4.5	130
14	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016, 87, 978-987.	1.5	109
15	Extracellular Matrix Influences the Biogenesis of Amyloid Precursor Protein in Microglial Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 7104-7110.	1.6	68
16	Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. <i>Journal of Neurology</i> , 2008, 255, 480-487.	1.8	63
17	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1466-1471.	1.4	58
18	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015, 85, 1694-1701.	1.5	55

#	ARTICLE	IF	CITATIONS
19	Subtraction MR Images in a Multiple Sclerosis Multicenter Clinical Trial Setting. <i>Radiology</i> , 2009, 250, 506-514.	3.6	47
20	Transforming growth factor $\hat{1}^2$ mediates increase of mature transmembrane amyloid precursor protein in microglial cells. <i>FEBS Letters</i> , 1994, 342, 267-272.	1.3	46
21	Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study. <i>Archives of Neurology</i> , 2007, 64, 1292.	4.9	46
22	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 605-617.	1.7	44
23	Scheduled versus Pro Re Nata Dosing in the VIEW Trials. <i>Ophthalmology</i> , 2015, 122, 2497-2503.	2.5	42
24	Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 1017.	4.5	37
25	Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. <i>Multiple Sclerosis Journal</i> , 2005, 11, 227-231.	1.4	33
26	Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. <i>Multiple Sclerosis Journal</i> , 2012, 18, 181-195.	1.4	33
27	Alzheimer's Disease $\hat{1}^2$ A4 Protein Release and Amyloid Precursor Protein Sorting Are Regulated by Alternative Splicing. <i>Journal of Biological Chemistry</i> , 1996, 271, 13208-13214.	1.6	32
28	Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study. <i>Archives of Neurology</i> , 2009, 66, 1345-52.	4.9	32
29	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. <i>Brain Imaging and Behavior</i> , 2019, 13, 1361-1374.	1.1	27
30	MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. <i>BMC Neurology</i> , 2009, 9, 19.	0.8	19
31	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2014, 20, 234-242.	1.4	19
32	MICROPERIMETRIC ASSESSMENT OF RETINAL SENSITIVITY IN EYES WITH DIABETIC MACULAR EDEMA FROM A PHASE 2 STUDY OF INTRAVITREAL AFLIBERCEPT. <i>Retina</i> , 2015, 35, 687-694.	1.0	17
33	Biological response genes after single dose administration of interferon $\hat{1}^2$ -1b to healthy male volunteers. <i>Journal of Neuroimmunology</i> , 2008, 199, 115-125.	1.1	15
34	Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis. <i>Clinical Therapeutics</i> , 2012, 34, 1132-1144.	1.1	13
35	Body mass index as a predictor of MS activity and progression among participants in BENEFIT. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1277-1285.	1.4	12
36	Variability in detection and quantification of interferon $\hat{1}^2$ -1b-induced neutralizing antibodies. <i>Journal of Neuroinflammation</i> , 2012, 9, 129.	3.1	9

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of interferon beta-1b sc in older RRMS patientsâ€™a posthoc analysis of the BEYOND study. Journal of Neurology, 2013, 260, 1838-1845.	1.8	9
38	Molekulare Medizin der Alzheimer-Krankheit. , 1999, , 195-236.		5
39	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology, 2015, 262, 2466-2471.	1.8	4